People · Operator
Named in public records as an officer, director or promoter · active 2011–2022 · Other, Pharmaceuticals, Biotech / Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Platelet BioGenesis, Inc. | — | Other | Series B | $72.9M | $426.7M | 2017 |
| Amylyx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $65.1M | $1.0B | 2016 |
| Forma Therapeutics Holdings LLC | — | Other | Series C | $60.1M | $171.5M | 2011 |
| Luna Pharmaceuticals, Inc. | — | Biotech / Pharma | Series A | $10.5M | $148.6M | 2016 |
| Ambergen, Inc. | — | Biotechnology | Series A | $5.0M | $77.1M | 2022 |
Peter Finn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Finn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter B. Finn | 1 | 11 |
| Isaac Cheng | 1 | 9 |
| Kevin Murphy | 1 | 9 |
| Joshua Cohen | 1 | 8 |
| Amy Wolf | 1 | 6 |
| Richard Murray | 1 | 5 |
| Steven Altschuler | 1 | 5 |
| Mark McDade | 1 | 5 |
| KEVIN M MURPHY | 1 | 3 |
| Alexis A. Borisy | 1 | 3 |
| Thong-Yuen Poon | 1 | 3 |
| Chidozie Ugwumba | 1 | 3 |
| Steven Hall | 1 | 2 |
| Steve Altschuler | 1 | 2 |
| Steven Tregay, Ph.D. | 1 | 2 |
| Philip Reilly | 1 | 2 |
| Michael A. Foley | 1 | 2 |
| John GIllespie | 1 | 2 |
| STEPHEN CHUBB | 1 | 2 |
| Stephen D. Chubb | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.